Opinion|Videos|July 29, 2024

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

Video content above is prompted by the following question(s):

  • How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo